Biogen Inc. (NASDAQ: BIIB )’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

Algernon to Acquire NoBrainer - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

The blood test measures two subtypes of tau and amyloid proteins, which can indicate the presence of amyloid plaque in the ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby the following resolutions were made. Adoption of the income statement ...

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

BioArctic AB (BRCTF) reports a surge in revenue and profit, driven by strategic alliances and expanding market presence, while addressing future challenges.